We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for durvalumab (AstraZeneca Pty Ltd)
Active ingredients
durvalumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
IMFINZI in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of patients with resectable gastric or gastroesophageal junction (GOJ) adenocarcinoma
Therapeutic area
Oncology